CERE vs. LEGN, ASND, JAZZ, ITCI, VKTX, ROIV, ELAN, CYTK, IONS, and BPMC
Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Legend Biotech (NASDAQ:LEGN) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings, media sentiment and community ranking.
Legend Biotech has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Cerevel Therapeutics has a net margin of 0.00% compared to Cerevel Therapeutics' net margin of -181.75%. Cerevel Therapeutics' return on equity of -37.19% beat Legend Biotech's return on equity.
70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Cerevel Therapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Cerevel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cerevel Therapeutics received 98 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 66.52% of users gave Cerevel Therapeutics an outperform vote while only 63.33% of users gave Legend Biotech an outperform vote.
Legend Biotech presently has a consensus price target of $82.64, suggesting a potential upside of 81.96%. Cerevel Therapeutics has a consensus price target of $41.40, suggesting a potential downside of 2.98%. Given Cerevel Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Legend Biotech is more favorable than Cerevel Therapeutics.
In the previous week, Cerevel Therapeutics had 1 more articles in the media than Legend Biotech. MarketBeat recorded 2 mentions for Cerevel Therapeutics and 1 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.37 beat Cerevel Therapeutics' score of -0.99 indicating that Cerevel Therapeutics is being referred to more favorably in the news media.
Summary
Cerevel Therapeutics beats Legend Biotech on 10 of the 17 factors compared between the two stocks.
Get Cerevel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cerevel Therapeutics Competitors List
Related Companies and Tools
